

Product Name: VE-821 Revision Date: 01/10/2021

Product Data Sheet

VE-821

Cat. No.: A2521

CAS No.: 1232410-49-9
Formula: C18H16N4O3S


M.Wt: 368.41

Synonyms:

Target: Cell Cycle/Checkpoint

Pathway: ATM/ATR

Storage: Store at -20°C



Solvent & Solubility

≥62.5 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O

In Vitro

Preparing Stock Solutions	Solvent Concentration	1mg	5mg	10mg
	1 mM	2.7144 mL	13.5718 mL	27.1437 mL
	5 mM	0.5429 mL	2.7144 mL	5.4287 mL
	10 mM	0.2714 mL	1.3572 mL	2.7144 mL

Please refer to the solubility information to select the appropriate solvent.

Biological Activity

Reacting conditions:

Shortsummary	ATR kinase inhibitor			
IC ₅₀ & Target	13 nM/26 nM (Ki/IC50) (ATR)			
	Cell Viability Assay			
	Cell Line:	HFL1 cells; HCT116 cancer cells; H23 cancer cell line.		
	Preparation method:	The solubility of this compound in DMSO is >10 mM. General tips for obtaining		
In Vitro		a higher concentration: Please warm the tube at 37°C for 10 minutes and/or		
		shake it in the ultrasonic bath for a while. Stock solution can be stored below		
		-20°C for several months.		

	Applications:	HFL1 cells were pretreated with 10 μM VE-821 or DMSO before addition of 200
		μM cisplatin (Cis), 1 μM gemcitabine (Gem), 100 μM etoposide (Etop) or 5 Gy
		ionizing radiation (IR), VE-821 blocks Chk1 Ser345 phosphorylation under all
		conditions and inhibits H2AX phosphorylation in treatment with cisplatin and
		gemcitabine. In the H23 cancer cell line, VE-821 shows marked synergy with
	310	cisplatin in growth arrest.
In Vivo	Animal experiment	
	Applications:	A Particular

Product Citations

- 1. Li Z, Liu B, et al. "hDNA2 nuclease/helicase promotes centromeric DNA replication and genome stability." EMBO J. 2018 May 17. pii: e96729.PMID:29773570
- 2. Nanda Kumar Sasi, Flavie Coquel, et al. "DDK has a primary role in processing stalled replication forks to initiate downstream checkpoint signaling." bioRxiv. 2017.October 21.

See more customer validations on www.apexbt.com.

References

[1]. Reaper PM1, Griffiths MR, Long JM, Charrier JD, Maccormick S, Charlton PA, Golec JM, Pollard JR. Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nat Chem Biol, 2011, 7(7): 428-430.

Caution

FOR RESEARCH PURPOSES ONLY.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

APE BI

Specific storage and handling information for each product is indicated on the product datasheet. Most APExBIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Shortterm storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

APExBIO Technology

www.apexbt.com

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: info@apexbt.com

2 | www.apexbt.com



APE BIO

APE BIO

APE, BIO

APE BIO

APE BIO

APE BIO

APE BIO

APE BIO